NCT04772274View on ClinicalTrials.gov

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Healthy
Interventions
DRUG

Ustekinumab

45 mg, single-dose

Trial Locations (1)

Unknown

Biotrial Rennes, Rennes

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT04772274 - A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects | Biotech Hunter | Biotech Hunter